References
- Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
- Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22(22):5419.
- Surveillance Epidemiology and End Results (SEER). SEER cancer stat facts: myeloma 2018 [ cited 2018 Aug 23]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html
- National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. Multiple Myeloma. Version 2. 2019;2018. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
- Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396–406.
- FDA. Pomalidamide (POMALYST) prescribing information 2013 [ cited 2018 Sept 4]. Available from: https://www.fda.gov/Drugs/informationOnDrugs/ApprovedDrugs/ucm530249.htm
- FDA. Elotuzumab (EMPLICITI) prescribing information 2015 [ cited 2018 Sept 4]. Available from: https://www.fda.gov/Drugs/informationOnDrugs/ApprovedDrugs/ucm530249.htm
- FDA. Panobinostat (FARYDAK) prescribing information 2016 [ cited 2018 Sept 4]. Available from: https://www.fda.gov/Drugs/informationOnDrugs/ApprovedDrugs/ucm530249.htm
- FDA. Daratumumab (DARZALEX) prescribing information 2018 [ cited 2018 Oct 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761036s013lbl.pdf
- FDA. Ixazomib (NINLARO) prescribing information 2015 [ cited 2018 Sept 4]. Available from: https://www.fda.gov/Drugs/informationOnDrugs/ApprovedDrugs/ucm530249.htm
- FDA. Highlights of prescribing information KYPROLIS(R) (carfilzomib) 2016 [ cited 2018 Nov 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202714s015lbl.pdf
- Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
- Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
- Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
- Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
- Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
- Weisel K, Lentzsch S, Mateos MV, et al. Efficacy and safety of daratumumab, bortezomib and dexamethasone (DVD) versus bortezomib and dexamethasone (VD) in relapsed or refractory multiple myeloma (RRMM): updated analysis of CASTOR. European Hematology Association 22nd Annual Congress; June 24; Madrid, Spain. 2017.
- Gordan L. Site of care cost analysis true value of community oncology. 2018 Community Oncology Conference; April 12; Washington, DC. 2018.
- Bureau of Labor Statistics. Local area unemployment statistics 2005 [ cited 2019 Jun 27]. Available from: https://www.bls.gov/lau/laurdqa.htm#Q1
- Ruschak AM, Schimmer AD, Kay LE, et al. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. 2011;103(13):1007–1017.
- Zhu YX, Shi C-X, Bruins LA, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9(2):19.
- Jagannath S, Roy A, Kish J, et al., Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol. 2016;9(7): 707–717.
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
- Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–981.
- Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560.
- Friends of Cancer Research (FOCR). 8th annual Blueprint for Breakthrough forum: validating real-world endpoints for an evolving regulatory landscape 2019 [ updated 2019 Sept 18; cited 2020 Mar 25]. Available from: https://www.focr.org/sites/default/files/pdf/8th_Friends-Alexandria_RWE.pdf
- FDA. FDA grants accelerated approval to selinexor for multiple myeloma 2019 [ updated 2019 Jul 3; cited 2020 Mar 25]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-selinexor-multiple-myeloma
- Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763–1774.